H7N9 antigen + adjuvant SE

H7N9 antigen + adjuvant SE is a combination pandemic influenza vaccine candidate composed of an inactivated split-virus hemagglutinin (HA) antigen derived from the A/Shanghai/2/2013(H7N9) strain and formulated with the squalene-based oil-in-water emulsion adjuvant known as "SE" (manufactured by Infectious Disease Research Institute, IDRI). The addition of the SE adjuvant enhances immunogenicity, enabling dose-sparing by eliciting stronger antibody responses at lower HA doses compared to non-adjuvanted formulations. This approach aims to improve pandemic preparedness by increasing immune response efficiency and expanding available vaccine supply. Clinical studies have shown that vaccines using this formulation are safe and well-tolerated, though local reactogenicity (injection site pain) is more common than in non-adjuvanted vaccines. The primary indication is prevention of infection caused by avian influenza A(H7N9)[4].

Other names

H7N9 vaccine with SEH-7N9 vaccine with SEH 7N9 vaccine with SEH7N9 split-virus vaccine with SE adjuvantH-7N9 split-virus vaccine with SE adjuvantH 7N9 split-virus vaccine with SE adjuvant